No Prescription |
 |
 | ||
|
Mofilet Cellcept |
|
| ||
No Prescription » Prescription Drugs 11 » Mofilet Cellcept Mycophenolate is used for: Preventing organ rejection following kidney liver or heart transplants. This medicine is used in combination with other medicines. Mycophenolate (mye-koe-FEN-oh-late) belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who receive organ transplants. Mycophenolate is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal cardiac or hepatic transplants. Mycophenolate should be used concomitantly with cyclosporine and corticosteroids. Buy Mofilet Cellcept and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About Mofilet Cellcept: Product Type: Prescription Drugs 11 Mofilet ( Cellcept Generic Mycophenolate ) Mofilet (Cellcept Generic Mycophenolate) Cellcept Generic Mycophenolate 250mg Cellcept Generic Mycophenolate Mofilet
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
